© 2021 MJH Life Sciences and Contagion Live. All rights reserved.
© 2021 MJH Life Sciences™ and Contagion Live. All rights reserved.
July 23, 2021
A discussion as to why people with unstable housing living with HIV may not prefer telehealth versus consistent in-person care.
The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.
Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?
July 22, 2021
Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.
Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.
July 21, 2021
Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.
Impaired resilience was found to be associated with loneliness.
Virtual support services were crucial for providing continued care and education.
In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.
July 20, 2021
New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.